<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="7049240AnnGastroenterol-33-195 doi: 10.20524/aog.2020.0449 : Original Article Direct-acting antiviral treatment for" exact="chronic hepatitis" post="C in people who use drugs in a real-world"/>
 <result pre="doi: 10.20524/aog.2020.0449 : Original Article Direct-acting antiviral treatment for chronic" exact="hepatitis" post="C in people who use drugs in a real-world"/>
 <result pre="Medical School of National and Kapodistrian University of Athens, Hippokration" exact="General" post="Hospital, 114 Vas. Sofias Ave, Athens 11527, Greece, e-mail:"/>
 <result pre="high cure rates in people who inject drugs (PWID) with" exact="hepatitis" post="C virus (HCV) infection. There are concerns regarding lower"/>
 <result pre="with hepatitis C virus (HCV) infection. There are concerns regarding" exact="lower" post="response rates among PWID in real life. We evaluated"/>
 <result pre="Methods We performed a retrospective analysis of 174 PWID with" exact="chronic hepatitis" post="C who started DAAs in a Greek liver clinic"/>
 <result pre="We performed a retrospective analysis of 174 PWID with chronic" exact="hepatitis" post="C who started DAAs in a Greek liver clinic"/>
 <result pre="therapy and presented for SVR12 testing, 8/174 (4.6%) did not" exact="complete" post="treatment and 22/174 (12.6%) were LTFU. Overall SVR12 was"/>
 <result pre="follow up for SVR testing and general care. Direct-acting antivirals" exact="hepatitis" post="C virus infection people who inject drugs sustained virological"/>
 <result pre="for SVR testing and general care. Direct-acting antivirals hepatitis C" exact="virus infection" post="people who inject drugs sustained virological response lost to"/>
 <result pre="SVR testing and general care. Direct-acting antivirals hepatitis C virus" exact="infection" post="people who inject drugs sustained virological response lost to"/>
 <result pre="lost to follow up Introduction Approximately 10% of people with" exact="chronic hepatitis" post="C virus (HCV) infection globally are past or current"/>
 <result pre="to follow up Introduction Approximately 10% of people with chronic" exact="hepatitis" post="C virus (HCV) infection globally are past or current"/>
 <result pre="Approximately 10% of people with chronic hepatitis C virus (HCV)" exact="infection" post="globally are past or current illicit drug users [1]."/>
 <result pre="the main route of HCV transmission in developed countries. HCV" exact="infection" post="poses an important health issue among PWID, while in"/>
 <result pre="health issue among PWID, while in many countries the burden" exact="of liver" post="disease due to chronic hepatitis C in this population"/>
 <result pre="issue among PWID, while in many countries the burden of" exact="liver disease" post="due to chronic hepatitis C in this population is"/>
 <result pre="among PWID, while in many countries the burden of liver" exact="disease" post="due to chronic hepatitis C in this population is"/>
 <result pre="in many countries the burden of liver disease due to" exact="chronic hepatitis" post="C in this population is expected to increase over"/>
 <result pre="many countries the burden of liver disease due to chronic" exact="hepatitis" post="C in this population is expected to increase over"/>
 <result pre="WHO strategy for HCV elimination, by scaling-up treatment for HCV" exact="infection" post="in both the general population and the vulnerable population"/>
 <result pre="and the vulnerable population of PWID. The prevalence of HCV" exact="infection" post="in Greece is estimated to be between 0.83% and"/>
 <result pre="between 0.83% and 1.79% [22], while 20-40% of persons with" exact="chronic hepatitis" post="C have a history of illicit drug injections [23-25]."/>
 <result pre="0.83% and 1.79% [22], while 20-40% of persons with chronic" exact="hepatitis" post="C have a history of illicit drug injections [23-25]."/>
 <result pre="of illicit drug injections [23-25]. In the present study, our" exact="primary" post="objective was to evaluate the clinical outcome of HCV"/>
 <result pre="a retrospective analysis of a cohort that included PWID with" exact="chronic" post="HCV infection who had been treated with DAAs in"/>
 <result pre="analysis of a cohort that included PWID with chronic HCV" exact="infection" post="who had been treated with DAAs in our tertiary"/>
 <result pre="parallel drug use. A history of previous anti-HCV therapy, decompensated" exact="liver disease," post="liver transplantation, hepatitis B virus (HBV) or human immunodeficiency"/>
 <result pre="history of previous anti-HCV therapy, decompensated liver disease, liver transplantation," exact="hepatitis" post="B virus (HBV) or human immunodeficiency virus (HIV) coinfections,"/>
 <result pre="liver disease, liver transplantation, hepatitis B virus (HBV) or human" exact="immunodeficiency" post="virus (HIV) coinfections, or parallel drug use were not"/>
 <result pre="the stability of appointment attendance, mental or medical comorbidities and" exact="liver disease" post="stages were also taken into consideration for treatment initiation."/>
 <result pre="stability of appointment attendance, mental or medical comorbidities and liver" exact="disease" post="stages were also taken into consideration for treatment initiation."/>
 <result pre="treatment initiation. In Greece, reimbursement for DAAs was based on" exact="liver disease" post="stages until September 2018, so until June 2017 only"/>
 <result pre="initiation. In Greece, reimbursement for DAAs was based on liver" exact="disease" post="stages until September 2018, so until June 2017 only"/>
 <result pre="2017 and September 2018, public funding and DAA reimbursement was" exact="limited" post="to patients with liver stiffness â‰¥F2, whereas patients with"/>
 <result pre="HCV manifestations and individuals with other comorbidities, such as hemoglobinopathies," exact="end-stage renal disease," post="organ transplantation or HIV/HCV coinfection, were treated irrespectively of"/>
 <result pre="manifestations and individuals with other comorbidities, such as hemoglobinopathies, end-stage" exact="renal disease," post="organ transplantation or HIV/HCV coinfection, were treated irrespectively of"/>
 <result pre="the liver stiffness score. The chosen elastography cutoff values for" exact="liver fibrosis" post="stages were: stiffness &amp;lt;9 kPa, 9-12 kPa and &amp;gt;12kPa"/>
 <result pre="fibrosis (Metavir Score F0-F1-F2), severe fibrosis (Metavir score F3), and" exact="cirrhosis" post="(Metavir Score F4), respectively. The diagnosis of cirrhosis was"/>
 <result pre="F3), and cirrhosis (Metavir Score F4), respectively. The diagnosis of" exact="cirrhosis" post="was based on the transient elastography score (&amp;gt;12 kPa),"/>
 <result pre="F4), respectively. The diagnosis of cirrhosis was based on the" exact="transient" post="elastography score (&amp;gt;12 kPa), liver biopsy findings and clinical"/>
 <result pre="part of standard clinical care. During the first visit, a" exact="complete" post="blood count, liver function tests, HBV/HCV, HIV serology, quantitative"/>
 <result pre="taking into account the HCV genotype, and the presence of" exact="cirrhosis" post="and comorbidities. During the treatment period, all patients were"/>
 <result pre="RNA, 12 weeks after treatment completion. Individuals who did not" exact="complete" post="the SVR12 testing within 24 weeks after treatment completion"/>
 <result pre="within 24 weeks after treatment completion were considered as LTFU." exact="Failure" post="to respond to antiviral therapy was defined as detectable"/>
 <result pre="study was approved by the Ethics committee of the Hippokration" exact="General" post="Hospital of Athens and all the procedures followed were"/>
 <result pre="infected with genotype 5 or 6. Two patients had decompensated" exact="liver disease" post="at baseline with Child-Pugh-Turcotte scores C and B, and"/>
 <result pre="with genotype 5 or 6. Two patients had decompensated liver" exact="disease" post="at baseline with Child-Pugh-Turcotte scores C and B, and"/>
 <result pre="baseline with Child-Pugh-Turcotte scores C and B, and model for" exact="end-stage liver disease" post="scores 18 and 10, respectively. The DAA regimens and"/>
 <result pre="with Child-Pugh-Turcotte scores C and B, and model for end-stage" exact="liver disease" post="scores 18 and 10, respectively. The DAA regimens and"/>
 <result pre="Child-Pugh-Turcotte scores C and B, and model for end-stage liver" exact="disease" post="scores 18 and 10, respectively. The DAA regimens and"/>
 <result pre="completed treatment. Eight of the 174 patients (4.6%) did not" exact="complete" post="therapy: poor compliance was the main reason for early"/>
 <result pre="of pregnancy; and 2 patients were diagnosed with malignancies (acute" exact="leukemia" post="and rectal cancer) and discontinued DAA treatment on their"/>
 <result pre="period and no patient stopped therapy because of adverse events." exact="Anemia" post="(hemoglobin &amp;lt;10 g/dL) was reported in 2 patients receiving"/>
 <result pre="dose reduction in both cases. One patient died from progressive" exact="liver disease" post="during the first month of treatment. No deaths or"/>
 <result pre="reduction in both cases. One patient died from progressive liver" exact="disease" post="during the first month of treatment. No deaths or"/>
 <result pre="and a half years from a cohort of PWID with" exact="chronic" post="HCV infection treated with DAAs. Our results clearly showed"/>
 <result pre="half years from a cohort of PWID with chronic HCV" exact="infection" post="treated with DAAs. Our results clearly showed that DAAs"/>
 <result pre="goal. The efficacy of DAA therapy in PWID with HCV" exact="infection" post="has been examined in 2 large prospective studies, in"/>
 <result pre="in PWID groups. In the ITT analysis we clearly observed" exact="lower" post="SVR12 rates: 79.9% of our population achieved SVR12, with"/>
 <result pre="SVR12 rates: 79.9% of our population achieved SVR12, with the" exact="absence of" post="HCV RNA testing after treatment completion being the main"/>
 <result pre="testing after treatment completion being the main reason for the" exact="lower" post="SVR12. Our data are in accordance with other real-world"/>
 <result pre="in several real-world studies [12,19,27], although others [18,20,21] reported significantly" exact="lower" post="LTFU rates (0.6-2%). The different LTFU rates across the"/>
 <result pre="assessment after therapy and surveillance for the early diagnosis of" exact="hepatocellular carcinoma" post="are important clinical issues from an individual point of"/>
 <result pre="after therapy and surveillance for the early diagnosis of hepatocellular" exact="carcinoma" post="are important clinical issues from an individual point of"/>
 <result pre="individual point of view [30]. Identifying factors that can predict" exact="lower" post="adherence during treatment or loss during the follow-up period"/>
 <result pre="the younger population and the rather earlier stages of HCV" exact="disease" post="may explain the association between age and LTFU rates."/>
 <result pre="analysis regarding treatment uptake: a proportion of PWID with HCV" exact="infection" post="did not start treatment, despite the availability DAA, and"/>
 <result pre="our finding. Treatment adherence-enhancing strategies, including special nurses engaged in" exact="hepatitis" post="C treatment in the hospital settings, could be a"/>
 <result pre="patients discontinued treatment for non-liver-related reasons and 1 with decompensated" exact="disease" post="at baseline died from liver failure. In addition, the"/>
 <result pre="reasons and 1 with decompensated disease at baseline died from" exact="liver failure." post="In addition, the most common adverse event was anemia,"/>
 <result pre="Neither of these patients needed to discontinue treatment and their" exact="anemia" post="improved with ribavirin dose reduction. In addition, none of"/>
 <result pre="dose reduction. In addition, none of the treated PWID developed" exact="hepatocellular carcinoma" post="between treatment initiation and SVR12 testing. Our study had"/>
 <result pre="reduction. In addition, none of the treated PWID developed hepatocellular" exact="carcinoma" post="between treatment initiation and SVR12 testing. Our study had"/>
 <result pre="and therefore the results should not be generalized without caution." exact="Incomplete" post="or missing data, entry errors and differences between active"/>
 <result pre="design. However, despite the above limitations our data points were" exact="complete" post="(&amp;gt;95%) as regards the vast majority of the parameters"/>
 <result pre="Direct acting-antivirals (DAAs) are highly effective for the treatment of" exact="hepatitis" post="C virus (HCV) infection Compared to the general population,"/>
 <result pre="highly effective for the treatment of hepatitis C virus (HCV)" exact="infection" post="Compared to the general population, DAAs have shown similar"/>
 <result pre="trials in people who inject drugs (PWID) and have HCV" exact="infection" post="There has been evidence for lower response rates for"/>
 <result pre="(PWID) and have HCV infection There has been evidence for" exact="lower" post="response rates for PWID in a real-life setting Adherence"/>
 <result pre="Medical School of National and Kapodistrian University of Athens, Hippokration" exact="General" post="Hospital; Medical School of National and Kapodistrian University of"/>
 <result pre="Medical School of National and Kapodistrian University of Athens, Laiko" exact="General" post="Hospital, Athens, Greece References 1NelsonPKMathersBMCowieBet al.Global epidemiology of hepatitis"/>
 <result pre="Laiko General Hospital, Athens, Greece References 1NelsonPKMathersBMCowieBet al.Global epidemiology of" exact="hepatitis" post="B and hepatitis C in people who inject drugs:results"/>
 <result pre="Athens, Greece References 1NelsonPKMathersBMCowieBet al.Global epidemiology of hepatitis B and" exact="hepatitis" post="C in people who inject drugs:results of systematic reviewsLancet201137857158321802134"/>
 <result pre="people who inject drugs:results of systematic reviewsLancet201137857158321802134 2MyersRPKrajdenMBilodeauMet al.Burden of" exact="disease" post="and cost of chronic hepatitis C infection in CanadaCan"/>
 <result pre="of systematic reviewsLancet201137857158321802134 2MyersRPKrajdenMBilodeauMet al.Burden of disease and cost of" exact="chronic hepatitis" post="C infection in CanadaCan J Gastroenterol Hepatol20142824325024839620 3MartinNKVickermanPGrebelyJet al.Hepatitis"/>
 <result pre="systematic reviewsLancet201137857158321802134 2MyersRPKrajdenMBilodeauMet al.Burden of disease and cost of chronic" exact="hepatitis" post="C infection in CanadaCan J Gastroenterol Hepatol20142824325024839620 3MartinNKVickermanPGrebelyJet al.Hepatitis"/>
 <result pre="2MyersRPKrajdenMBilodeauMet al.Burden of disease and cost of chronic hepatitis C" exact="infection" post="in CanadaCan J Gastroenterol Hepatol20142824325024839620 3MartinNKVickermanPGrebelyJet al.Hepatitis C virus"/>
 <result pre="between sustained virological response and all-cause mortality among patients with" exact="chronic hepatitis" post="C and advanced hepatic fibrosisJAMA20123082584259323268517 5The Lancet. Towards elimination"/>
 <result pre="sustained virological response and all-cause mortality among patients with chronic" exact="hepatitis" post="C and advanced hepatic fibrosisJAMA20123082584259323268517 5The Lancet. Towards elimination"/>
 <result pre="C and advanced hepatic fibrosisJAMA20123082584259323268517 5The Lancet. Towards elimination of" exact="viral hepatitis" post="by 2030Lancet2016388308 6European Association for the Study of the"/>
 <result pre="and advanced hepatic fibrosisJAMA20123082584259323268517 5The Lancet. Towards elimination of viral" exact="hepatitis" post="by 2030Lancet2016388308 6European Association for the Study of the"/>
 <result pre="the Study of the Liver. EASL Recommendations on Treatment of" exact="Hepatitis" post="C 2018J Hepatol20186946151129650333 7GrebelyJHaireBTaylorLEet al.Excluding people who use drugs"/>
 <result pre="al.Excluding people who use drugs or alcohol from access to" exact="hepatitis" post="C treatments â€“Is this fair, given the available data?J"/>
 <result pre="fair, given the available data?J Hepatol20156377978226254264 8JainMKThamerMTherapondosGet al.Has access to" exact="hepatitis" post="C virus therapy changed for patients with mental health"/>
 <result pre="or substance use disorders in the direct-acting-antiviral period?Hepatology201969516330019478 9AsherAKPortilloCJCooperBADawson-RoseCVlahovDPageKAClinicians'views of" exact="hepatitis" post="C virus treatment candidacy with direct-acting antiviral regimens for"/>
 <result pre="10BaruaSGreenwaldRGrebelyJDoreGJSwanTTaylorLERestrictions for Medicaid reimbursement of sofosbuvir for the treatment of" exact="hepatitis" post="C virus infection in the United StatesAnn Intern Med201516321522326120969"/>
 <result pre="Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C" exact="virus infection" post="in the United StatesAnn Intern Med201516321522326120969 11AlimohammadiAHoleksaJThiamATruongDConwayBReal-world efficacy of"/>
 <result pre="reimbursement of sofosbuvir for the treatment of hepatitis C virus" exact="infection" post="in the United StatesAnn Intern Med201516321522326120969 11AlimohammadiAHoleksaJThiamATruongDConwayBReal-world efficacy of"/>
 <result pre="Intern Med201516321522326120969 11AlimohammadiAHoleksaJThiamATruongDConwayBReal-world efficacy of direct-acting antiviral therapy for HCV" exact="infection" post="affecting people who inject drugs delivered in a multidisciplinary"/>
 <result pre="multidisciplinary settingOpen Forum Infect Dis20185ofy12029992173 12ChristensenSBuggischPMaussSet al.Direct-acting antiviral treatment of" exact="chronic" post="HCV-infected patients on opioid substitution therapy:still a concern in"/>
 <result pre="clinical practice?Addiction201811386888229359361 13DoreGJAlticeFLitwinAHet al.collab: C-EDGE CO-STAR Study GroupElbasvir-grazoprevir to treat" exact="hepatitis" post="C virus infection in persons receiving opioid agonist therapy:a"/>
 <result pre="13DoreGJAlticeFLitwinAHet al.collab: C-EDGE CO-STAR Study GroupElbasvir-grazoprevir to treat hepatitis C" exact="virus infection" post="in persons receiving opioid agonist therapy:a randomized trialAnn Intern"/>
 <result pre="al.collab: C-EDGE CO-STAR Study GroupElbasvir-grazoprevir to treat hepatitis C virus" exact="infection" post="in persons receiving opioid agonist therapy:a randomized trialAnn Intern"/>
 <result pre="safety of ledipasvir/sofosbuvir with and without ribavirin in patients with" exact="chronic" post="HCV genotype 1 infection receiving opioid substitution therapy:analysis of"/>
 <result pre="and without ribavirin in patients with chronic HCV genotype 1" exact="infection" post="receiving opioid substitution therapy:analysis of Phase 3 ION trialsClin"/>
 <result pre="Dis2016631405141127553375 15GrebelyJDoreGJZeuzemSet al.Efficacy and safety of sofosbuvir/velpatasvir in patients with" exact="chronic hepatitis" post="C virus infection receiving opioid substitution therapy:analysis of Phase"/>
 <result pre="15GrebelyJDoreGJZeuzemSet al.Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic" exact="hepatitis" post="C virus infection receiving opioid substitution therapy:analysis of Phase"/>
 <result pre="and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C" exact="virus infection" post="receiving opioid substitution therapy:analysis of Phase 3 ASTRAL trialsClin"/>
 <result pre="safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus" exact="infection" post="receiving opioid substitution therapy:analysis of Phase 3 ASTRAL trialsClin"/>
 <result pre="Alcohol Depend201717721422028618285 17GrebelyJDalgardOConwayBet al.collab: SIMPLIFY Study GroupSofosbuvir and velpatasvir for" exact="hepatitis" post="C virus infection in people with recent injection drug"/>
 <result pre="17GrebelyJDalgardOConwayBet al.collab: SIMPLIFY Study GroupSofosbuvir and velpatasvir for hepatitis C" exact="virus infection" post="in people with recent injection drug use (SIMPLIFY):an open-label,"/>
 <result pre="al.collab: SIMPLIFY Study GroupSofosbuvir and velpatasvir for hepatitis C virus" exact="infection" post="in people with recent injection drug use (SIMPLIFY):an open-label,"/>
 <result pre="Hepatol2018315316129310928 18BoglioneLMornesePinna SDe NicolÃ²Aet al.Treatment with direct-acting antiviral agents of" exact="hepatitis" post="C virus infection in injecting drug users:A prospective studyJ"/>
 <result pre="SDe NicolÃ²Aet al.Treatment with direct-acting antiviral agents of hepatitis C" exact="virus infection" post="in injecting drug users:A prospective studyJ Viral Hepat20172485085728345206 19ButnerJLGuptaNFabianCHenrySShiJMTetraultJMOnsite"/>
 <result pre="NicolÃ²Aet al.Treatment with direct-acting antiviral agents of hepatitis C virus" exact="infection" post="in injecting drug users:A prospective studyJ Viral Hepat20172485085728345206 19ButnerJLGuptaNFabianCHenrySShiJMTetraultJMOnsite"/>
 <result pre="hepatitis C virus infection in injecting drug users:A prospective studyJ" exact="Viral" post="Hepat20172485085728345206 19ButnerJLGuptaNFabianCHenrySShiJMTetraultJMOnsite treatment of HCV infection with direct acting"/>
 <result pre="drug users:A prospective studyJ Viral Hepat20172485085728345206 19ButnerJLGuptaNFabianCHenrySShiJMTetraultJMOnsite treatment of HCV" exact="infection" post="with direct acting antivirals within an opioid treatment programJ"/>
 <result pre="drugs treated with direct acting antiviral therapy at an urban" exact="primary" post="care clinicInt J Drug Policy20174719620128811158 22PapatheodoridisGSypsaVKantzanouMNikolakopoulosIHatzakisAEstimating the treatment cascade"/>
 <result pre="care clinicInt J Drug Policy20174719620128811158 22PapatheodoridisGSypsaVKantzanouMNikolakopoulosIHatzakisAEstimating the treatment cascade of" exact="chronic hepatitis" post="B and C in Greece using a telephone surveyJ"/>
 <result pre="clinicInt J Drug Policy20174719620128811158 22PapatheodoridisGSypsaVKantzanouMNikolakopoulosIHatzakisAEstimating the treatment cascade of chronic" exact="hepatitis" post="B and C in Greece using a telephone surveyJ"/>
 <result pre="hepatitis B and C in Greece using a telephone surveyJ" exact="Viral" post="Hepat20152240941525209157 23GiannousisIPPapatheodoridisGVDeutschMJet al.The burden and recent epidemiological changes of"/>
 <result pre="23GiannousisIPPapatheodoridisGVDeutschMJet al.The burden and recent epidemiological changes of the main" exact="chronic" post="liver diseases in a Greek referral tertiary centreEur J"/>
 <result pre="tertiary centreEur J Gastroenterol Hepatol20102217217919738477 24SypsaVTouloumiGTassopoulosNCet al.Reconstructing and predicting the" exact="hepatitis" post="C virus epidemic in Greece:increasing trends of cirrhosis and"/>
 <result pre="predicting the hepatitis C virus epidemic in Greece:increasing trends of" exact="cirrhosis" post="and hepatocellular carcinoma despite the decline in incidence of"/>
 <result pre="hepatitis C virus epidemic in Greece:increasing trends of cirrhosis and" exact="hepatocellular carcinoma" post="despite the decline in incidence of HCV infectionJ Viral"/>
 <result pre="C virus epidemic in Greece:increasing trends of cirrhosis and hepatocellular" exact="carcinoma" post="despite the decline in incidence of HCV infectionJ Viral"/>
 <result pre="hepatocellular carcinoma despite the decline in incidence of HCV infectionJ" exact="Viral" post="Hepat20041136637415230860 25TriantosCKonstantakisCTselekouniPKalafateliMAggeletopoulouIManolakopoulosSEpidemiology of hepatitis C in GreeceWorld J Gastroenterol2016228094810227688651"/>
 <result pre="decline in incidence of HCV infectionJ Viral Hepat20041136637415230860 25TriantosCKonstantakisCTselekouniPKalafateliMAggeletopoulouIManolakopoulosSEpidemiology of" exact="hepatitis" post="C in GreeceWorld J Gastroenterol2016228094810227688651 26ManolakopoulosSDeutschMJAnagnostouOet al.Substitution treatment or"/>
 <result pre="not be contraindications for antiviral treatment in drug users with" exact="chronic hepatitis" post="CLiver Int2010301454146020846344 27MorrisLSmirnovAKvassayAet al.Initial outcomes of integrated community-based hepatitis"/>
 <result pre="be contraindications for antiviral treatment in drug users with chronic" exact="hepatitis" post="CLiver Int2010301454146020846344 27MorrisLSmirnovAKvassayAet al.Initial outcomes of integrated community-based hepatitis"/>
 <result pre="chronic hepatitis CLiver Int2010301454146020846344 27MorrisLSmirnovAKvassayAet al.Initial outcomes of integrated community-based" exact="hepatitis" post="C treatment for people who inject drugs:Findings from the"/>
 <result pre="J Drug Policy20174721622028666635 28ReadPLothianRChronisterKet al.Delivering direct acting antiviral therapy for" exact="hepatitis" post="C to highly marginalised and current drug injecting populations"/>
 <result pre="highly marginalised and current drug injecting populations in a targeted" exact="primary" post="health care settingInt J Drug Policy20174720921528587943 29WelzelTMHinrichsenHSarrazinCet al.Real-world experience"/>
 <result pre="interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of" exact="chronic hepatitis" post="C virus infection in the German Hepatitis C RegistryJ"/>
 <result pre="regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic" exact="hepatitis" post="C virus infection in the German Hepatitis C RegistryJ"/>
 <result pre="ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C" exact="virus infection" post="in the German Hepatitis C RegistryJ Viral Hepat20172484084928342229 30KoustenisK-RKoutliEKranidiotiHet"/>
 <result pre="and dasabuvir for the treatment of chronic hepatitis C virus" exact="infection" post="in the German Hepatitis C RegistryJ Viral Hepat20172484084928342229 30KoustenisK-RKoutliEKranidiotiHet"/>
 <result pre="treatment of chronic hepatitis C virus infection in the German" exact="Hepatitis" post="C RegistryJ Viral Hepat20172484084928342229 30KoustenisK-RKoutliEKranidiotiHet al.Tu1506 â€“Adherence to follow-up"/>
 <result pre="hepatitis C virus infection in the German Hepatitis C RegistryJ" exact="Viral" post="Hepat20172484084928342229 30KoustenisK-RKoutliEKranidiotiHet al.Tu1506 â€“Adherence to follow-up of people who"/>
 <result pre="people who inject drugs (PWID) after the successful treatment of" exact="chronic hepatitis" post="C with direct-acting antivirals (DAA)Gastroenterology2019156S-1346 31HajarizadehBCunninghamEBReidHLawMDoreGJGrebelyJDirect-acting antiviral treatment for"/>
 <result pre="who inject drugs (PWID) after the successful treatment of chronic" exact="hepatitis" post="C with direct-acting antivirals (DAA)Gastroenterology2019156S-1346 31HajarizadehBCunninghamEBReidHLawMDoreGJGrebelyJDirect-acting antiviral treatment for"/>
 <result pre="hepatitis C with direct-acting antivirals (DAA)Gastroenterology2019156S-1346 31HajarizadehBCunninghamEBReidHLawMDoreGJGrebelyJDirect-acting antiviral treatment for" exact="hepatitis" post="C among people who use or inject drugs:a systematic"/>
 <result pre="meta-analysisLancet Gastroenterol Hepatol2018375476730245064 32HellardMRollsDASacks-DavisRet al.The impact of injecting networks on" exact="hepatitis" post="C transmission and treatment in people who inject drugsHepatology2014601861187025163856"/>
 <result pre="the availability of direct antiviral agents (DAAs) enough to treat" exact="chronic hepatitis" post="C (CHC) and achieve HCV elimination among people who"/>
 <result pre="availability of direct antiviral agents (DAAs) enough to treat chronic" exact="hepatitis" post="C (CHC) and achieve HCV elimination among people who"/>
 <result pre="(PWUD)?What do the real world data suggest?7th International Symposium on" exact="Hepatitis" post="Care in Substance Users. Cascais/Portugal, 19-21 September2018"/>
</results>
